Piper Sandler Has Lowered Expectations for Inozyme Pharma (NASDAQ:INZY) Stock Price

Inozyme Pharma (NASDAQ:INZY) had its target price lowered by stock analysts at Piper Sandler from $30.00 to $23.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock.

Other equities analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Inozyme Pharma in a research note on Tuesday. Needham & Company LLC lowered their price target on shares of Inozyme Pharma from $23.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday. Raymond James started coverage on Inozyme Pharma in a report on Thursday, December 12th. They set an “outperform” rating and a $26.00 price objective for the company. Wedbush restated an “outperform” rating and issued a $7.00 target price (down previously from $12.00) on shares of Inozyme Pharma in a research note on Monday. Finally, Wells Fargo & Company cut their price target on Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, January 13th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $14.56.

Inozyme Pharma Price Performance

NASDAQ INZY opened at $1.08 on Tuesday. Inozyme Pharma has a 1 year low of $0.98 and a 1 year high of $7.80. The business’s fifty day moving average is $1.52 and its two-hundred day moving average is $3.28. The stock has a market capitalization of $69.38 million, a P/E ratio of -0.69 and a beta of 1.32. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68.

Institutional Trading of Inozyme Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in INZY. Jane Street Group LLC increased its holdings in shares of Inozyme Pharma by 7.5% during the 3rd quarter. Jane Street Group LLC now owns 49,460 shares of the company’s stock valued at $259,000 after acquiring an additional 3,443 shares during the last quarter. OneDigital Investment Advisors LLC grew its holdings in Inozyme Pharma by 51.5% during the third quarter. OneDigital Investment Advisors LLC now owns 20,000 shares of the company’s stock valued at $105,000 after purchasing an additional 6,800 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Inozyme Pharma by 31.0% in the third quarter. JPMorgan Chase & Co. now owns 28,928 shares of the company’s stock valued at $151,000 after purchasing an additional 6,851 shares during the period. Palumbo Wealth Management LLC lifted its stake in shares of Inozyme Pharma by 52.3% in the fourth quarter. Palumbo Wealth Management LLC now owns 23,281 shares of the company’s stock worth $64,000 after buying an additional 7,995 shares during the last quarter. Finally, American Century Companies Inc. boosted its holdings in shares of Inozyme Pharma by 11.6% during the 4th quarter. American Century Companies Inc. now owns 79,349 shares of the company’s stock worth $220,000 after buying an additional 8,263 shares during the period. Institutional investors and hedge funds own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.